Loading
Every dated change on the records linked to Gastric & gastro-oesophageal junction cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy
Co-primary endpoints including OS met (July 2026); numbers pending.
PFS 12.
A milestone in how this cancer is treated.
CLDN18.2+ advanced gastric/GEJ adenocarcinoma, previously treated
Median progression-free survival 3.
OS 14.
Interim OS 17.
EFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
First-line persistent/recurrent/metastatic cervical cancer with chemotherapy ± bevacizumab; first-line gastric cancer with chemotherapy
Second-line ESCC after chemotherapy; first-line HER2-negative gastric/GEJ with chemotherapy (PD-L1 ≥1)
1L CLDN18.2+ HER2- gastric/GEJ; 19 Sep 2024
CLDN18.2+ HER2- gastric cancer (first approval, March 2024)
First-line CLDN18.2+ (≥75%), HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with fluoropyrimidine/platinum chemotherapy
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer
Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer
First-line gastric or gastro-oesophageal junction adenocarcinoma with chemotherapy (ORIENT-16)
Confirmed durable responses to trastuzumab deruxtecan in a Western population after progression on trastuzumab.
OS HR 0.
Weight gain over 5%: 60% vs 9%; appetite improvement 43% vs 13%.
OS 15.
SPOTLIGHT OS 18.
A milestone in how this cancer is treated.
HER2+ gastric cancer; HER2-expressing urothelial cancer
DFS 22.
Higher response rate and longer progression-free survival with pembrolizumab added to trastuzumab and chemotherapy, with benefit concentrated in PD-L1-positive tumours; accelerated approval in May 2021, later limited to PD-L1 combined positive score of 1 or more.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
CPS ≥5: OS 14.
Higher objective response rate and longer overall survival with trastuzumab deruxtecan than with irinotecan or paclitaxel; approved in January 2021.
Pembrolizumab alone was non-inferior to chemotherapy for overall survival in PD-L1-positive disease; pembrolizumab plus chemotherapy was not superior to chemotherapy; large benefit in the microsatellite-unstable subgroup.
Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal
Refractory metastatic gastric/GEJ cancer (TAGS)
Perioperative FLOT improved overall survival over ECF or ECX in resectable gastric and junctional adenocarcinoma.
Laparoscopic distal gastrectomy was non-inferior to open surgery for five-year overall survival in stage I gastric cancer, with fewer wound complications.
A milestone in how this cancer is treated.
Gastric / GEJ adenocarcinoma, CPS ≥1
Nivolumab improved overall survival over placebo in heavily pretreated advanced gastric cancer; approved in Japan in September 2017.
Trastuzumab emtansine did not improve overall survival over taxane chemotherapy in previously treated HER2-positive gastric cancer.
A milestone in how this cancer is treated.
Gastric cancer; NSCLC
Advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines
OS 9.
A milestone in how this cancer is treated.
HER2 testing extended to gastric and GEJ adenocarcinoma with trastuzumab (ToGA)
HER2+ gastric cancer
OS 13.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.